BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA: Aegerion Pharmaceuticals, Inc. (AEGR) Drug Cuts Cholesterol but Has Liver Safety Risk


10/15/2012 8:16:37 AM

Aegerion Pharmaceuticals Inc. (AEGR) rose in early trading after a U.S. regulatory staff report said the company’s plan to manage risk associated with its drug supports approval in adults with the most life-threatening forms of severely high cholesterol who have limited treatment options. Aegerion gained 14 percent to $18.14 at 9:02 a.m. New York time after the Food and Drug Administration staff report today on lomitapide. The report was released prior to an advisory panel meeting on Oct. 17. The agency is scheduled to make a final decision on the treatment, Cambridge, Massachusetts-based Aegerion’s lead product candidate, by the end of December. The once-daily pill aims to treat a genetic condition known as familial hypercholesterolemia that causes abnormalities in liver cells responsible for clearing LDL, or low density lipoprotein, particles from the blood.

Read at Bloomberg
Read at Nasdaq

Bloomberg
Nasdaq
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES